BMYBristol Myers Squibb

Healthcare

$59.11+34% 1Y

$59.11

$41.6752 weeks$68.08

Is the price fair?

Excellent

Undemanding: modest expectations priced in, cheap against its own history, and cheap vs its sector.

3 good

What the price assumes~−4% a year

Priced for a decline (~−4% a year). The price demands less than its three-year revenue growth of 3% a year, expectations look modest.

Vs its own P/E rangecheaper than 81% of its own historyderived

Cheap vs its own history: P/E 13.0 vs a 17.4 median over 31 quarters (−25% vs median).

Vs sector (EV/EBIT)12.0×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 78% of the market

FCF yieldbetter than 85% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What BMY's price assumes

Bristol Myers Squibb trades at 13.0× earnings against 26.2× for the median Drug Manufacturers - General name, cheaper than its own group.

13.0

Trailing P/E · Drug Manufacturers - General median 26.2 · cheaper than the typical name in its group

Price / sales: 2.24
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 10%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: −4.1%
Growth the price implies · The price pays for −4.1% free cash flow growth a year for a decade; the business has delivered +2.2% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 4.94
EV / EBITtoday's price, trailing year to Jun 30, 2026: 12.0
EV / salestoday's price, trailing year to Jun 30, 2026: 2.91
Healthcare median P/E509 names: 26.2
Drug Manufacturers - General median P/E16 names: 26.2
Free cash flow, trailing twelve months: $11.4B
Market capitalisation: $110.3B
3-year revenue growth: +2.9%
3-year free cash flow growth: +2.2%

What the market has paid for these earnings: 31 quarters of its own multiple × $4.54 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$64.26
Its own P/E history, median	$79.20
Its own P/E history, upper quartile	$98.99
52-week range	$41.67 – $68.08
Today	$59.11

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Cheap stocks by free cash flow yield Quality at a reasonable price

Drug Manufacturers, General

The closest names by size in the same industry